BIO 2026: With two CNS programs in front of FDA and a third that has received breakthrough therapy designation, Praxis Precision Medicines isn't taking its success for granted or slowing down

1 day ago
1 min read

CEO Marcio Souza walks us through essential tremor and the mechanism of ulixacaltamide, and also comments on a recent seizure trial that did not succeed. Plus, preparing for potential commercial launches and how he thinks about M&A.

https://vimeo.com/1203978684

Coverage brought to you by

Recent Posts

See All

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm

BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here

BIO 2026: With two CNS programs in front of FDA and a third that has received breakthrough therapy designation, Praxis Precision Medicines isn't taking its success for granted or slowing down

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight